Cannabis extract taken by the mouth could potentially provide additional relief for patients with chemotherapy-induced nausea and vomiting (CINV), according to the results of a first-of-its-kind phase 2/3 study published in the Journal of Clinical Oncology.
In a recent study of 147 adults with refractory nausea and/or vomiting during moderate or high-emetic-risk chemotherapy randomly received oral capsules either THC:CBD or placebo that were required to be taken three times daily from one to five days.
During the study, researchers learned that patients in each group had a complete response—defined as no vomiting or retching and no use of rescue medications during hours 0–120 after the first cycle of chemotherapy. The complete response rate was threefold higher in patients assigned to THC:CBD compared with placebo.
Despite the promising results, the study also revealed increased rates of adverse events among patients taking THC, including sedation and dizziness. Experts have praised the trial for overcoming numerous challenges associated with cannabis research in oncology, yet they emphasize the need for broader representation in clinical studies, particularly among Black patients.
You May Also Like
Historically, cancer trials have lacked diversity, often excluding minorities from critical research that could tailor treatments to their specific needs. Dr. Lila Thompson, an oncologist and advocate for equitable healthcare, highlighted the implications of this lack of representation. “Without diverse participation, we risk overlooking how different populations respond to treatments,” she stated.
The path forward involves not only assessing the efficacy of THC compared to other antiemetics but also navigating the complexities of cannabis research in cancer care. This ongoing research is crucial for optimizing treatment strategies and improving the quality of life of Black American cancer patients battling the debilitating effects of chemotherapy-induced nausea and vomiting.
